BETABAT
Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes
| Coordinatore | UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Sito del progetto | http://betabat.ulb.ac.be/index.php |
| Totale costo | 8˙005˙516 € |
| EC contributo | 5˙999˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-10-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
BE (BRUXELLES) | coordinator | 1˙354˙000.00 |
| 2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 994˙000.00 |
| 3 |
UNIVERSITE DE LAUSANNE
Organization address
city: LAUSANNE contact info |
CH (LAUSANNE) | participant | 497˙000.00 |
| 4 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 485˙000.00 |
| 5 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 482˙000.00 |
| 6 |
UNIVERSITAT DE BARCELONA
Organization address
address: GRAN VIA DE LES CORTS CATALANES 585 contact info |
ES (BARCELONA) | participant | 474˙000.00 |
| 7 |
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Organization address
address: NORTH TORREY PINES ROAD 10901 contact info |
US (LA JOLLA CA) | participant | 450˙000.00 |
| 8 |
SIRION BIOTECH GMBH
Organization address
address: AM KLOPFERSPITZ 19 contact info |
DE (PLANEGG MARTINSRIED) | participant | 411˙000.00 |
| 9 |
DNA VISION SA
Organization address
address: AVENUE G LEMAITRE 25 contact info |
BE (GOSSELIES) | participant | 356˙000.00 |
| 10 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: TEKNIIKANTIE 4 A contact info |
FI (ESPOO) | participant | 286˙333.60 |
| 11 |
Steno Diabetes Center A/S
Organization address
address: Niels Steensens Vej 2 contact info |
DK (Gentofte) | participant | 209˙666.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'A reduction in functional pancreatic beta cell mass is the key feature of type 1 and type 2 diabetes. Beta cell failure is exacerbated in the context of obesity and insulin resistance. Brown adipose tissue (BAT) is a highly metabolic organ, mediating energy dissipation and glucose disposal, thus contributing to maintain energy balance. BAT dysfunction contributes to obesity and impaired glucose metabolism, increasing functional demand on the beta cells. The cellular dysfunction of beta cells and BAT in diabetes is the fruit of defective signal transduction and organelle function, and the vulnerability to these molecular defects may be modulated by diabetes genes. To identify the crosstalk and pathways responsible for beta cell and BAT dysfunction and beta cell apoptosis in diabetes at its real level of complexity, this consortium will use cutting edge genetics, functional (epi)genomics, molecular biology and computational tools to reach an accurate organelle and cell diagnosis. This diagnosis will be used to define novel targets for intervention to prevent dysfunction and facilitate recovery of functionally impaired metabolic tissues. Some of these targets have already been identified by consortium members, including endoplasmic reticulum (ER) stress and mitochondrial dysfunction and apoptosis. Since many of these targets are related to dysfunction of specific organelles, we will focus on the novel concept of organelle therapy, aiming to preserve mitochondrial and ER function by the use of viral vectors and small molecule chemical probes. We will thus follow a two-pronged approach, namely a focused approach to restore known and specific cellular/organelle dysfunctions and a systems biology approach to identify novel targets for intervention. This, in combination with high throughput screening of large compound libraries, will translate discoveries into innovative therapeutic strategies that halt destruction and facilitate recovery of cell dysfunction in diabetes.'
Introduzione (Teaser)
When beta cells of the pancreas and brown adipose tissue (BAT) malfunction, they become "partners in crime" for the development of diabetes. A European initiative is identifying the molecular mechanisms involved.